Wednesday 28 October 2020

MHRA joins new body


As part of post Brexit arrangements, the MHRA has joined the Australia-Canada-Singapore-Switzerland Consortium of regulators.

The consortium will change its name to the Access Consortium.

According to the press release, Access Consortium partners will work together with the primary aim of providing patients across the five countries with timely access to high quality, safe, and effective therapeutic products. Through the addition of the UK, the new combined population to be covered by the consortium is approximately 145 million people.

Any pharmaceutical companies submitting applications to some, or all, of the consortium member countries will benefit from having products evaluated for marketing in Access countries simultaneously with reduced evaluation times. Additionally, the Access Consortium will update the guidance for industry on how product applications may be considered for marketing authorization across the five countries, Australia, Canada, Singapore, Switzerland, and the UK. Is this of advantage to BPL?

MHRA press release link:

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers